natgillin/translations-raw huggingface dataset:
The agonist for use according to claim 6, wherein said therapeutically effective amount of the a adrenergic receptor agonist is for administration prior to said physical trauma to the skin, cutaneous vasculature, subcutaneous vasculature and/or surrounding tissues. 
Agonist za uporabu u skladu sa zahtjevom 1, naznačen time što purpura je purpura uzrokovana kirurškim postupkom, te pri čemu se agonist alfa adrenergijskog receptora primjenjuje prije kirurškog zahvata, tijekom kirurškog zahvata, nakon kirurškog zahvata, ili njihovih kombinacija.
The minimally invasive skin treatment device of Claim 13, wherein the needle comprises: a lumen; a tip for piercing a dermis; and at least two injection ports in communication with the lumen, wherein the ports are linearly disposed along an outer surface of the needle and flush with a side of the needle. 
Uređaj za minimalno invazivni tretman kože u skladu s patentnim zahtjevom 13, naznačen time, da igla uključuje: lumen; vršak za probijanje kože i HR P20160498 T1 najmanje dva otvora za ubrizgavanje u komunikaciji s lumenom, pri čemu su otvori linearno postavljeni duž vanjske površine igle i u ravnini su s jednom stranom igle.
fructose and glucose) linked to each other in the carbohydrate chain of one oligo- or polysaccharide molecule. 
fruktoze i glukoze) međusobno povezanih u ugljikohidratni lanac oligosaharidne ili polisaharidne molekule.
Accordingly, the Tg depends on the composition of the mixture. 
Cc) ucrtavanje T.,g po sastavu smjesa.
The protein of embodiment 1, wherein the elastase recognition sequence comprises SEQ ID NO:13. 
(a) sekvenca za prepoznavanje elastaze ima prolinski ostatak lociran na poziciji P2;
Package according to anyone of claims 1 to 17, characterised in that the cutout (20; 93; 103) of the outer shell (2; 92; 102) is provided in the front wall (10) of the outer shell (2; 92; 102). 
Omot za pakiranje u skladu s bilo kojim od patentnih zahtjeva 1 do 20, naznačen time što je izrezani dio (20; 93; 103; 122) vanjske ljuske (2; 92: 102; 112) predviđen u prednjoj stijenki (10; 120) vanjske ljuske (2; 92: 102; 112).
It is noted that the order of the at least one filter applicable for the first type of connection and the at least one filter applicable for the second type of connection may be inverted in case the number of filters required for the second type of connection equals or is larger than the number of filters required for the first type of connection. 
- - gdje se barem jedan filter, koji je primjenjiv za prvu vrstu veze, nalazi prije barem jednog drugog filtera koji je primjenjiv za drugu vrstu veze, naznačeno time što se poredak barem jednog filtera, koji je primjenjiv za prvu vrstu veze, i barem jednog filtera koji je primjenjiv za drugu vrstu veze, može preokrenuti u slučaju da poraste broj filtera koji su potrebni za drugu vrstu veze.
The process of embodiment 4, wherein the infectious agent is selected from the group consisting of: respiratory syncytial virus; measles virus; Coxsackie viruses; echoviruses; enteroviruses; orthoreoviruses; rotaviruses; and infectious bursal disease virus. The process of any preceding claim, wherein the mammalian cell line is a Vero cell line, and wherein the infectious agent is selected from the group consisting of: Metapneumoviruses of the Paramyxoviridae family; Rubulaviruses of the Paramyxoviridae family; Togaviridae; Coronaviridae; Rhinoviruses of the Picornaviridae family; varicella zoster virus; Polyomaviridae; porcine circoviruses; porcine picornaviruses; Chlamydia bacteria; and Parvoviruses. 
Postupak za pripremanje cjepiva protiv gripe iz virusa gripe izraslog u kulturi Vero stanične linije, koji sadrži stupanj u kojem se uzgojeni virus i/ili cjepivo i/ili kultura testira na prisutnost infekcijskog agensa koji može rasti u navedenoj staničnoj liniji, ali koji ne raste u embriju kokošjih jaja, naznačen time, da je navedeni infekcijski agens jedan ili više od sljedećih patogena: Pneumovirinae; Metapneumovirusi iz familije Paramyxoviridae; Rubulavirusi iz familije Paramyxoviridae; Coronaviridae; Rhinovirusi iz familije Picornaviridae; Varicella Zoster virus; BK polyomavirus, JC polyomavirus; Echovirusi; Coxgackievirusi od Fnterovirusa iz familije Picornaviridae, Rotavirus, svinjski picornavirusi; Parvovirus; Circovirus; bakterija Chlamydia; Reoviridae kod sisavaca.
Method as claimed in one or more of the claims 2-6, wherein the shaping of the piece of plate material is performed on plate material manufactured from High-Density Polyethylene. 
Postupak prema jednom ili više zahtjeva 2-5, naznačen time da se oblikovanje komada pločastog materijala provodi na pločastom materijalu proizvedenom od polietilena visoke gustoće.
The method of item 3 in which the initial dose ranges is from 0.1 mg/kg to 1 mg/kg of rhASM. 
() primjenu incijalne niske netoksične doze KSM, pri čemu je navedena inicijalna doza raspona od 0,05 mg/kg do 0,275 mg/kg KSM-a;
The qualitative and quantitative detection of the protein Serum amyloid P-component (SAP, SAMP, SwissProt No: P02473) in a biological fluid from a pregnant woman and 
C) Prognoza i/ili dijagnoza jest pozitivna ako je kvantitativna vrijednost proteinskog seruma amiloidne komponente P (SAP, SAMP, SwissProt br.
The method of claim 1, wherein said TSLP antagonist antigen binding protein comprises either: a light chain variable domain sequence selected from the group consisting of: 
2. -Anti-TSLP ljudsko protutijelo iz patentnog zahtjeva 1, sadrži: a. varijabilnu domenu lakog lanca izabranu iz grupe koja sadrži: i.
is selected from the series consisting of halogen, (C1-C4)-alkyl, HO-, (C1-C4)-alkyl-O- and R16-N(R17)-, and two substituents R13 bonded to adjacent ring carbon atoms in R7, together with the carbon atoms carrying them, can form a 5-membered to 7-membered mono-unsaturated ring which comprises 0, 1 or 2 identical or different ring heteroatoms selected from the series consisting of nitrogen, oxygen and sulfur, and which is unsubstituted or substituted by one or more identical or different substituents selected from the series consisting of fluorine and (C1-C4)-alkyl; 
R13 se bira iz skupine koju čine halogen, (C,-Cx)-alkil, HO-, (C,-C4)-alkil-O- i R16-N(R17)-, gdje dva supstituenta R13 vezana na susjedni atomi ugljika u R7 prstenu, zajedno s atomima ugljika koji ih nose, mogu tvoriti 5-eročlani do 7-eročlani mono-nezasićeni prsten, koji sadrži 0, 1 ili 2 ista ili različita heteroatoma u prstenu, koje se bira iz skupine koju čine dušik, kisik i sumpor, te koji je nesupstituiran ili je supstituiran s jednim ili više istih ili različitih supstituenata, koje se bira iz skupine koju čine fluor i (C,-C,)-alkil,
The solution was filled into 25 ml vials using an automatic pump and silicone platinum-cured tubing 3.2 mm. 
Otopina je punjena u ampule od 25 ml primjenom automatske pumpe i cijevi obrađene silicijem i platinom 3.2 mm.
The compound of claim 1 having Formula II: 
Tvar iz patentnog zahtjeva 1 koja ima formulu II:
A pharmaceutical composition for use in the treatment of depression, alcohol addiction and/or dependence, premenstrual tension, premenstrual syndrome or premenstrual dysphoric disorder, comprising 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one or a pharmaceutically-acceptable salt or solvate thereof, and one or more pharmaceutically-acceptable excipients, wherein the composition provides steady state plasma levels of 3a-hydroxy-3B-methoxymethyl-21-(1'-imidazolyl)-5a-pregnan-20-one in a range of from 5 ng/mL to 500 ng/mL for a duration of from 12 h to 24 h following administration. 
Farmaceutski sastav, naznačen time da sadrži 3a-hidroksi-3B-metoksimetil-21-(1’-imidazolil)-5a-pregnan-20-on ili njegovu farmaceutski prihvatljivu sol ili solvat i jedan ili više farmaceutski prihvatljivih ekscipijenata za upotrebu u liječenju opsesivno- kompulzivnog poremećaja, posttraumatskog stresnog poremećaja ili socijalnog anksioznog poremećaja u ljudskom subjektu, pri čemu sastav daje stacionarno stanje razina u plazmi 3a-hidroksi-3B-metoksimetil-21-(1’-imidazolil)-5a-pregnan-20-ona u rasponu od 5 ng/ml do 500 ng/ml u trajanju od 6 sati do 24 sata nakon davanja.
Information on the direct and indirect effects of buprenorphine on the fetus is essential for determining its potential for treatment of the pregnant opiate addict. 
Informiranje o izravnim i neizravnim učincima buprenorfina na fetus je osnova za određivanje njegovog potencijala za liječenje trudne ovisnice o opijatu.
The combination of claim 19, wherein the nucleoside analog is selected from among fluoropyrimidine 5-fluorouracil, 5-fluoro-2′-deoxycytidine, cytarabine, gemcitabine, troxacitabine, decitabine, Azacytidine, pseudoisocytidine, Zebularine, Ancitabine, Fazarabine, 6-azacytidine, capecitabine, N4-octadecyl-cytarabine, elaidic acid cytarabine, fludarabine, cladribine, clofarabine, nelarabine, forodesine, and pentostatin, or derivatives thereof. 
Kombinacija ili kompozicija za upotrebu prema bilo kojem od patentnih zahtjeva 5-14, naznačena time što je nukleozidni analog odabran između fluoropirimidin 5-fluorouracila, 5-fluoro-2'-deoksicitidina, citarabina, gemcitabina, troksacitabina, decitabina, azacitidina, pseudoizocitidina, zebularina, ancitabina, fazarabina, 6- HR P20181187 T1 azacitidina, kapecitabina, N4-oktadecil-citarabina, citarabina elaidinske Kiseline, fludarabina, kladribina, klofarabina, nelarabina, forodesina i pentostatina, ili njihovih derivata.
Process for the preparation of hemipentahydrate monosodium salt of [1-hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid g of [1-hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid was suspended in 100 mL of water and heated to a temperature of 100-102° C., and 6.58 g of 45% aqueous sodium hydroxide was then added dropwise until pH 4.9-5.0 was obtained. 
Postupak za pripravu hemi-pentahidratne mononatrijeve soli [1-hidroksi-2-(3-piridiniljetiliden] bisfosfonske kiseline 20 g [1-hidroksi-2-(3-piridiniljetiliden] bisfosfonske kiseline suspendira se u 100 ml vode i zagrije na temperaturu od 100-102 "C, i kap po kap se u nju doda 6,58 g 45% natrijeve lužine dok se ne dobije pH od 4.9-5.0, Ova reakcijska smjesa potom vrije kroz 2 sata, te se doda 1.25 aktiviranog ugljena.
to form Compound (H): 
(G) kako bi se dobilo Spoj (H)
The present invention also relates to the use of the compounds of the invention in combination with other active agents such as those belonging to the class of a-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, thiazolidinedione and the like. 
Prikazani izum se također odnosi na uporabu spojeva prema izumu u kombinaciji s ostalim aktivnim sredstvima poput onih koja pripadaju inhibitorima a-glukozidaze, inhibitorima aldoza reduktaze, bigvanidima, HMG-CoA reduktaza inhibitorima, inhibitorima sinteze skvalena, fibratima, LDL katabolizam poboljšivačima, angiotenzin konvertaza inhibitorima (ACE), poboljšivačima sekrecije inzulina, tiazolidindionima i slično.
21a: diffusion slits A diffusion pipe (13) comprising: 
Cijev za difuziju (zraka) (13), naznačena time, da sadržava:
The process of claim 12, where said step of heating the reaction mixture produces crude 1,1,1,2,3-pentachloropropane, and where the crude 1,1,1,2,3-pentachloropropane reactor effluent from a reactor in which 1,1,1,2,3-pentachloropropane. is formed is dehydrochlorinated in the presence of ferric chloride contained within the reactor effluent from the reactor in which 1,1,1,2,3-pentachloropropane is formed and in the presence of ferric chloride added to the system after the 1,1,1,2,3-pentachloropropane is formed. 
Postupak iz patentnog zahtjeva 12, pri čemu se 1,1,1,2,3-pentakloropropan dehidroklorira u prisustvu željezovog(IlI) klorida i (1) sirovi 1,1,1,2,3-pentakloropropan koji se izljeva iz reaktora u kojem se 1,1,1,2,3- pentakloropropan stvara izravno se dehidroklorira, bez prethodnog pročišćavanja 1 bez dodavanja katalizatora ili reagencija, ili (1) pročišćeni 1,1,1,2,3-pentakloropropan se dovodi u reaktivni sustav destilacije i željezov(IlI) klorid se zasebno dodaje u sustav.
The ophthalmic aqueous solution according to any one of claims 1 to 7 wherein the stabilizing agent is selected from the group consisting of ethylenediaminetetraacetic acid and salts thereof, sodium nitrite, ascorbic acid, L-ascorbic acid stearate, sodium hydrogensulfite, alphathioglycerin, erythorbic acid, cysteine hydrochloride, citric acid, tocopherol acetate, potassium dichloroisocyanurate, 2,6-di-t-butyl-4-methylphenol, soybean lecithin, sodium thioglycollate, sodium thiomalate, natural vitamin E, tocopherol, ascorbyl pasthyminate, sodium pyrosulfite, butylhydroxyanisole, 1,3-butylene glycol, pentaerythtyl tetrakis[3-(3,5-di-t-butyl-4-hydroxyphenyl)]propionate, propyl gallate, 2-mercaptobenzimidazole and oxyquinoline sulphate. 
Oftalmološka vodena otopina prema bilo kojem od zahtjeva 1 do 9, naznačena time da je neionsko površinski aktivno sredstvo izabrano iz skupine koja sadrži etilendiamintetra octenu kiselinu i njezine soli, natrijev nitrit, askorbinsku kiselinu, stearat L-askorbinske kiseline, natrijev hidrogensulfit, alfatioglicerin, eritorbinsku kiselinu, cistein hidroklorid, limunsku kiselinu, tokoferol acetat, kalijev dikloroizocijanurat, 2,6-di-t-butil-4-metilfenol, sojin lecitin, natrijev tioglikolat, natrijev tiomalat, prirodni vitamin E, tokoferol, askorbil pastiminat, natrijev pirosulfit, butilhidroksianizol, 1,3-butilen glikol, pentaeritil tetrakis[3-(3,5-di-t-butil-4-hidroksifenil)]propionat, propil galat, 2-merkaptobenzimidazol i oksikinolin sulfat.
Process B typically gives rise to dihydrotetrabenazine isomers in which the hydrogen atoms at the 2- and 3-positions have a cis relative orientation. 
Postupak B obično daje izomere dihidrotetrabenazina u kojima atomi vodika u položajima 2- i 3- imaju cis relativnu orijentaciju.
For ultrafilter sanitization, around 500 mL of 0.5 M NaOH were filtered for at least 30 minutes, and then the ultrafilter was rinsed with purified water until the permeate pH is below 7.5. 
Za sterilizaciju ultrafiltera, filtrirano je oko 500 mL 0.5 M NaOH najmanje 30 min, a tada je ultrafilter bio opran s pročišćenom vodom nakon što pH permeata padne ispod 7.5.
The fusion protein for use as claimed in any one of claims 1 to 7 wherein said mitochondrial disorder is selected from the group consisting of encephalopathy and liver failure that is accompanied by stormy lactic acidosis, hyperammonemia and coagulopathy, Alpers Disease, Barth syndrome, Beta-oxidation Defects, Carnitine-Acyl-Carnitine Deficiency, Carnitine Deficiency, Co-Enzyme Q10 Deficiency, Complex I Deficiency, Complex II Deficiency, Complex III Deficiency, Complex IV Deficiency, Complex V Deficiency, COX Deficiency, CPEO, KSS, LCHAD, Leigh Disease or Syndrome, LHON, LIC (Lethal Infantile Cardiomyopathy), Luft Disease, MELAS, MERRF, Mitochondrial Cytopathy, Mitochondrial Myopathy, MNGIE, NARP, and Pyruvate Dehydrogenase Deficiency. 
Fuzijski protein za uporabu iz bilo kojeg od patentnih zahtjeva 1 do 7 pri čemu je navedeni mitohondrijski poremećaj odabran iz grupe koja se sastoji od encefalopatije 1 zatajenja jetre koje je praćeno burnom laktatnom acidozom, hiperamonijemijom i koagulopatijom, Alperove bolesti, sindroma Barth, nedostatka u beta-oksidaciji, nedostatka karnitin-acilkarnitina, nedostatka karnitina, nedostatka koenzima Q10, nedostatka kompleksa I, nedostatka kompleksa II, nedostatka kompleksa III, nedostatka kompleksa IV, nedostatka kompleksa V, nedostatka COX, CPEO, KSS, LCHAD, Leigh bolesti ili sindroma, LHON, LIC (letalne novorođenačke kardiomiopatije), Luftove bolesti, MELAS, MERRF, mitohondrijske citopatije, mitohondrijske miopatije, MNGIE, NARP i nedostatka piruvat dehidrogenaze.
A compound as claimed in claims 1, or 6, or a pharmaceutically acceptable salt or ester thereof, or a pharmaceutical composition as claimed in claim 2, wherein m is 1 and R1 is Cl and in position 6 of the spiro oxindole. 
Spoj prema zahtjevima 1 ili 6, ili njegova farmaceutski prihvatljiva sol ili njegov farmaceutski prihvatljiv ester, ili farmaceutski sastav prema zahtjevu 2, naznačen(a) time, da m je 11 RI je CI 1 to je na poziciji 6 od spirooksindola.
as is disclosed in EP-A-1 180 564) or some expanded polymer, such as EPS (expanded polystyrene), for example that as offered by Unidek under the name Unidek EPS which is modified according to NEN 6065/6066 in order to obtain fire retarding properties. 
kako je objavljeno u EP-A- 1 180 564) ili neki ekspandirani polimer, kao EPS (ekspandirani polistiren), na primjer onaj kojeg nudi Unidek pod nazivom Unidek EPS modificiran prema NEN 6065/6066 kako bi se postiglo svojstvo usporavanja gorenja.
The pharmaceutical composition for use of claim 27 wherein the disease or disorder is COPD. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 25, naznačen time što je bolest ili poremećaj COPD.
The compound as recited in Claim 1 wherein said chronic hyperkinetic movement disorder is a tic. 
Spoj za uporabu prema zahtjevu 1, naznačen time da navedeni kronični poremećaj hiperkinetičkog pokreta je tik.
represents a hydrogen atom, a methyl group or an ethyl group 
R, predstavlja atom vodika, metilnu skupinu ili etilnu skupinu;
and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, wherein the term "optionally substituted phenyl" means a phenyl group which can be substituted in any position by one or more halogen, C1-4 alkyl, C1-4 alkoxy, trifluoromethyl and/or cyano group, or combinations thereof. 
i/ili njegovi geometrijski izomeri i/ili stereoizomeri i/ili dijastereomeri i/ili soli i/ili hidrati i/ili solvati i/ili polimorfi, gdje izraz “opcijski supstituirani fenil” znači fenilna skupina koja može biti supstituirana na bilo kojoj poziciji s jednom ili više halogen, C1-4 alkil, C1-4 alkoksi, trifluorometil i/ili cijano skupinom, ili njihovim kombinacijama.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropidin. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-iljamid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
The mouse of claim 1, wherein the at least two low affinity human FcYR genes are FcYRIIA and FcYRIIIA. 
Miš prema zahtjevu 1, naznačen time, što su najmanje dva humana gena FcyR s niskim afinitetom FcyRIIA i FcyRIIIA.
After 3 hours the catalyst is filtered off and the filtrate evaporated at 30°: white solid. 
Nakon tri sata katalizator se ukloni filtriranjem i filtrat se evaporira na 30 €: bijela krutina.
The method of claim 1, wherein: said cells in said input composition comprise suspension cells; 
navedene stanice u navedenom ulaznom sastavu čine suspenziju stanica;
The compounds of the present invention include: 
Datum objave europske prijave patenata:
The composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-iljamid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
Funke et al (Arzneim.-Forsch./Drug Res. 40 (1999), 536-539) have described Physicochemical properties of asenapine maleate. 
Funke i sur. (Arzneim-Forsch./Drug Res. 40 (1999), 536-539) su opisali fizičko-kemijska svojstva asenapin maleata.
A method for preparing Montelukast acid of formula 1 or the sodium salt thereof, comprising the step of coupling a thiol compound of formula 2 with a Montelukast intermediate of formula 3 in the presence of a base in a medium comprising an ionic liquid compound selected from the group consisting of the compounds of formulae 4a to 4e: wherein, R1 is hydrogen, methyl, or ethyl; 
Postupak dobivanja Montelukastove kiseline formule 1 ili njezine natrijeve soli, naznačen time što se sastoji u koraku kondenziranja tiolnog spoja formule 2 SH CO2R: s Montelukastovim međuproduktom formule 3 u prisutnosti baze, u mediju koji sadrži tekući ionski spoj, kojeg se bira iz skupine koju čine spojevi formula 4a do 4e: gdje
A compound for use as a medicament, according to claim 3, said compound being selected in the group consisting of 6B-ethyl-3a,7B-dihydroxy-5B-cholan-24-ol and 6a-ethyl-3a,7a-dihydroxy-24-nor-5B-cholan-23-ol. 
Spoj za uporabu kao lijek, u skladu s patentnim zahtjevom 3, naznačen time, da je rečeni spoj odabran iz skupine koja se sastoji od 6B-etil-3a,7B-dihidroksi-5B-kolan-24-ola i 6a-etil- 3a,7a-dihidroksi-24-nor-5B-kolan-23-ola.
A medicament comprising a compound represented by the formula (I) wherein R1 is as defined in claim 1, or a salt thereof, in combination with a calcium antagonist for the prophylaxis or treatment of diseases in which insulin resistance is involved. 
N. CH3CH,O- N (I) gdje R! je kao definiran u zahtjevu 1, ili njegovu sol, u kombinaciji s antagonistom kalcija za profilaksu ili liječenje oboljenja u kojemu je uključena inzulinska rezistencija.
The compound, salt, or composition of claim 18, wherein said cancer is selected from cancer of the colon, pancreatic cancer, breast cancer, prostate cancer, lung cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, renal cancer, cancer of the head and neck, lymphoma, leukemia, and melanoma. 
Spoj, sol ili sastav prema patentnom zahtjevu 32, naznačen time da je spomenuti rak odabran od raka kolona, raka gušterače, raka dojke, raka prostate, raka pluća, raka mozga, raka jajnika, raka vrata materice, raka testisa, raka bubrega, raka glave i vrata, limfoma, leukemije i melanoma.
The pharmaceutical composition according to claim 10 for treating or diagnosing a VAP-1 mediated inflammatory disorder selected from the group consisting of arthritides and connective tissue diseases, inflammatory bowel diseases, dermatoses, multiple sclerosis, inflammatory neuropathy, inflammatory myopathy, acute disseminated encephalomyelitis, vasculitis of the central nervous system, Sjögrens syndrome, diabetes, systemic lupus erythematosus, asthma, inflammatory liver disease, Graves disease and thyroiditis. 
Farmaceutski sastav u skladu s patentnim zahtjevom 10 za liječenje ili dijagnostiku VAP-1 posredovanog upalnog poremećaja odabranog iz grupe koja se sastoji od artritisa 1 bolesti vezivnog tkiva, upalnih bolesti crijeva, dermatoze, multiple skleroze, upalne neuropatije, upalne miopatije, akutnog diseminiranog encefalomijelitisa, vaskulitisa središnjeg živčanog sustava, Sjogrenovog sindroma, dijabetesa, sustavnog eritemskog lupusa, astme, upalne bolesti jetre, Gravesove bolesti i tiroiditisa.
The pharmaceutical composition according to claim 1 or 2, wherein the neuraminidase inhibitor is zanamivir. 
Farmaceutski pripravak u skladu sa zahtjevom 1 ili 2, naznačen time, da je neuraminidaza inhibitor zanamivir.
The pharmaceutical composition according to claim 7 or claim 8, wherein said first Omega-3 fatty acid ester is EPA and said second Omega-3 fatty acid ester is DHA. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 7 ili patentnim zahtjevom 8, naznačen time što je navedeni prvi ester omega-3 masne kiseline EPA, a navedeni drugi ester omega-3 masne kiseline je DHA.
The monolithic intravaginal ring of claim 1, wherein the pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid is present in a concentration of 0.1% to 10% by total weight of the ring. 
Monolitni intravaginalni prsten u skladu s patentnim zahtjevom 1, naznačen time, da su farmaceutski prihvatljiv ugljikovodik ili glicerolni esteri masnih kiselina prisutni u koncentraciji od 0,1 % do 10 % ukupne mase prstena.
In fig. 8d a base part 5 corresponding to the base unit 3 in fig 8A is shown. 
Na slici 8d prikazan je osnovni dio 5 koji odgovara osnovnoj jedinici 3 sa slike 8A.
Preferably, the suspension is heated for a period of not less than 2 hours. 
Preferirano je suspenzija zagrijavana u periodu ne manjem od 2 sata.